Is this you?
Request access for Alliance Biomedical Research with your @alliancebiomedical.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Alliance Biomedical Research
Unclaimed profileSite Network · Greenville, SC · ~11 sites
Intera lens
ICP 6Lift (cardio sample) 0.86Recruit soph 0.14
Quality Scorecard (1–100)
Overall70Recruit60Ops77Sponsor69Ther75
Performance (observed)
Historical trials
207
Completed
109
Terminated/Withdrawn
32
Completion rate
77%
Active now
64
Phase 2
59
Phase 3
134
Realized enrollment
459,473
First study year
1999
Years active
27
Match confidence
high
Enrollment velocity (inf)
17,018
Therapeutic
Areas
Phase II-IV; diverse therapeutic areas (cardiovascular, metabolic, CNS focus implied)
Specialties
Phase II-IV trials, multi-specialty
Breadth (conditions)
452
Languages
English
States
Southeast (SC, NC, GA, TN, AL, VA, WV, TX, FL)
Recruitment (web observed)
Advertises recruitment
Yes
Capability notes
Strong enrollment focus; excellent track record exceeding enrollment targets
Relationships
Sponsors
Pfizer; Children's Oncology Group; Eli Lilly and Company; AbbVie; National Cancer Institute (NCI); Hoffmann-La Roche
CROs
IQVIA Pty Ltd; PPD, Part of Thermo Fisher Scientific; Premier Research; Syneos Health; Teva Branded Pharmaceutical Products R&D LLC
Owner / parent
Great Point Partners (growth recapitalization Sept 2016); Founded 2004
Funding
PE: Great Point Partners (2016 growth recapitalization)
Expansion
11 SE US locations as of 2016
Capacity & people
Investigators
—
Coordinators
—
CEO
Unknown
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
Unknown
Tech & DCT
Builds tech
Unknown
Home visits
N
DCT / decentralized
N
Tech stack
Unknown
Recruiting visible
Y
Notes
Southeast-focused SMO with 11 sites across 8+ states. Founded 2004, PE-backed (Great Point Partners). Enrollment-constrained focus (exceeds targets). Phase II-IV diverse. 2016 recapitalization for growth (de novo expansion, tuck-in acquisitions). Good fit: enrollment-focused, PE-backed, multistate. Weakness: no visible tech stack/innovation signals.
Recommendation features (sample indication)
Ind fit 1.00Liftability 0.86Overall70
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.